{"name":"Mitotech, SA","slug":"mitotech-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"High dose - SkQ1","genericName":"High dose - SkQ1","slug":"high-dose-skq1","indication":"Age-related macular degeneration (AMD)","status":"phase_3"},{"name":"Low Dose - SkQ1","genericName":"Low Dose - SkQ1","slug":"low-dose-skq1","indication":"Age-related macular degeneration (AMD)","status":"phase_3"},{"name":"SkQ1 Ophthalmic Solution","genericName":"SkQ1 Ophthalmic Solution","slug":"skq1-ophthalmic-solution","indication":"Treatment of dry age-related macular degeneration","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SkQ1 Vehicle Solution","genericName":"SkQ1 Vehicle Solution","slug":"skq1-vehicle-solution","indication":"Dry age-related macular degeneration","status":"phase_3"}]}],"pipeline":[{"name":"High dose - SkQ1","genericName":"High dose - SkQ1","slug":"high-dose-skq1","phase":"phase_3","mechanism":"SkQ1 is a mitochondrial-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.","indications":["Age-related macular degeneration (AMD)","Dry eye disease","Other age-related ocular conditions"],"catalyst":""},{"name":"Low Dose - SkQ1","genericName":"Low Dose - SkQ1","slug":"low-dose-skq1","phase":"phase_3","mechanism":"SkQ1 is a mitochondria-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.","indications":["Age-related macular degeneration (AMD)","Dry eye disease"],"catalyst":""},{"name":"SkQ1 Ophthalmic Solution","genericName":"SkQ1 Ophthalmic Solution","slug":"skq1-ophthalmic-solution","phase":"phase_3","mechanism":"SkQ1 Ophthalmic Solution is a mitochondrially-targeted antioxidant that aims to protect retinal cells from oxidative stress.","indications":["Treatment of dry age-related macular degeneration"],"catalyst":""},{"name":"SkQ1 Vehicle Solution","genericName":"SkQ1 Vehicle Solution","slug":"skq1-vehicle-solution","phase":"phase_3","mechanism":"SkQ1 is a mitochondrially-targeted antioxidant that aims to delay the onset of age-related diseases.","indications":["Dry age-related macular degeneration","Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOcTFsdWh2ejBfaDNLQ1RrdmxPUTFpVkxaUXhLRHB0SDJBc2R5ZkUyaTNhMWp3OGJJZVB5b3pheUhVNTFqVVl5TVVlZml5Rk5qSHBMelVxV1BORjVySEJrYkxPRVk4SU1QaC1sNno2M2JoU0R5UXFyTDFCcWtTa0F5RF90aXZqeDNOT2dudWVGbkoweEdaZnpsYmRNeGl1aVJSR1ZHczJ4TlphWkRlcU1DbEU0V1RjWHBDQmVoaF9zRzdSZXc4S0RWQXozRkVmNEY0U2Q0eUIybWs4TmZrMnAxbFdocDAyNkZYRjQxejN0SEVqVGlZUXVVbFlLUHZoSG9OTUE?oc=5","date":"2023-05-18","type":"trial","source":"PR Newswire","summary":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry - PR Newswire","headline":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxORFFTN0xxZUlQRldmR2JGczNZbkZqNGNiZFBFX0Z5S2hQdGFVWjFoaTJCNFdYN2NCTUFrMEtBRzY4VVRQN2lTakVEQ2N2N2dUZS1xaWxQMFZTNjd3aTVGRDlDTklXc2hoTnNCdFhROEU1a3d2MUdiT29CbGN0Nlg4aW5INnJucHE3eUtIWDFFWXFZcW16?oc=5","date":"2019-04-15","type":"pipeline","source":"Fierce Biotech","summary":"Mitotech: a Dry Eye treatment aimed at mitochondria - Fierce Biotech","headline":"Mitotech: a Dry Eye treatment aimed at mitochondria","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}